-

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

  • BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time
  • RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time
  • Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time
  • Jefferies Global Healthcare Conference on Wednesday, June 4 at 11:05 AM Eastern Time
  • Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 10 at 11:20 AM Eastern Time

The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English
Hashtags
#GILD
#GILDInvestorConferences
#GileadInvestorConferences
#GileadInvestorRelations
#GileadSciences

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com

Social Media Profiles
Gilead Sciences Facebook
Gilead Sciences Instagram
Gilead Sciences LinkedIn
Gilead Sciences YouTube
More News From Gilead Sciences, Inc.

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained u...

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and...

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10, 2025, Amsterdam, furthering Gilead’s commitment to transform the lives of people living with liver disease. New data to be presented at EASL will include a subgroup analysis from ASSURE, an ongoing open-label study, and an analysis of the Phase 3 RESPONSE trial and the open-label extension. Data w...
Back to Newsroom